Form 8-K - Current report:
SEC Accession No. 0001683168-25-008624
Filing Date
2025-11-21
Accepted
2025-11-21 17:19:16
Documents
18
Period of Report
2025-11-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 54978
2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION cns_ex0301.htm EX-3.1 10287
3 2020 EQUITY PLAN (AS AMENDED AND RESTATED) cns_ex1001.htm EX-10.1 89682
7 GRAPHIC image_005.jpg GRAPHIC 182651
8 GRAPHIC image_006.jpg GRAPHIC 128843
9 GRAPHIC image_007.jpg GRAPHIC 29016
10 GRAPHIC image_008.jpg GRAPHIC 113623
  Complete submission text file 0001683168-25-008624.txt   973327

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cnsp-20251117.xsd EX-101.SCH 3017
5 XBRL LABEL FILE cnsp-20251117_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE cnsp-20251117_pre.xml EX-101.PRE 22360
20 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3805
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 251509030
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)